Last reviewed · How we verify

diazepam 20 mg

Viatris Specialty LLC · FDA-approved active Small molecule Quality 5/100

diazepam 20 mg is a Small molecule drug developed by Viatris Specialty LLC. It is currently FDA-approved.

Diazepam 20 mg, marketed by Viatris Specialty LLC, holds a significant position in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established mechanism and broad therapeutic use, which has contributed to its sustained market presence. The primary risk is the potential increase in competition following the patent expiry in 2028, which could impact revenue and market share.

At a glance

Generic namediazepam 20 mg
SponsorViatris Specialty LLC
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about diazepam 20 mg

What is diazepam 20 mg?

diazepam 20 mg is a Small molecule drug developed by Viatris Specialty LLC.

Who makes diazepam 20 mg?

diazepam 20 mg is developed and marketed by Viatris Specialty LLC (see full Viatris Specialty LLC pipeline at /company/viatris-specialty-llc).

What development phase is diazepam 20 mg in?

diazepam 20 mg is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing